CASI Pharmaceuticals Obtains Delisting Decision from NASDAQ Hearings Panel
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 25 2026
0mins
Source: moomoo
- Delisting Decision: Casi Pharmaceuticals has received a decision regarding its delisting from the NASDAQ hearings panel.
- Impact on Company: The outcome of the hearings may significantly affect the company's future operations and market presence.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
